Defining the Optimal Threshold Scores for Adult Autism Subthreshold Spectrum (AdAS Spectrum) in Clinical and General Population.
AdAS Spectrum
Autism Spectrum Disorder
Autistic traits
Diagnostic threshold
Psychometric instrument
RAADS
Journal
Clinical practice and epidemiology in mental health : CP & EMH
ISSN: 1745-0179
Titre abrégé: Clin Pract Epidemiol Ment Health
Pays: United Arab Emirates
ID NLM: 101245735
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
07
2020
revised:
27
10
2020
accepted:
23
11
2020
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
The Adult Autism Subthreshold Spectrum (AdAS Spectrum) is a recently developed instrument tailored to assess the broad range of full-threshold as well as sub-threshold manifestations related to the autism spectrum. Although it has proved to be a valuable instrument for quantitative assessment of autistic symptoms, the AdAS Spectrum still lacks validated diagnostic thresholds. The aim of this study was to define the best cut-off scores of the AdAS Spectrum for determining the presence of subthreshold autistic traits as well as a clinically significant autism spectrum disorder (ASD). Our sample was composed of 39 patients with full-blown ASD, 73 subjects with autistic traits, and 150 healthy controls. Subjects were evaluated by trained psychiatrists, who performed a clinical diagnosis according to DSM-5 and then assessed with the AdAS Spectrum and the Autism Spectrum Quotient. Our results showed that the most discriminant cut-off scores were 70 for identifying subjects with full-blown ASD, and 43 for determining the presence of significant autistic traits. The threshold values proposed here showed satisfying levels of specificity and sensibility, as well as a good agreement with the diagnosis according to DSM-5 criteria, confirming the validity of the AdAS Spectrum as a psychometric tool for measuring ASD-related conditions in the clinical and general population.
Sections du résumé
BACKGROUND
BACKGROUND
The Adult Autism Subthreshold Spectrum (AdAS Spectrum) is a recently developed instrument tailored to assess the broad range of full-threshold as well as sub-threshold manifestations related to the autism spectrum. Although it has proved to be a valuable instrument for quantitative assessment of autistic symptoms, the AdAS Spectrum still lacks validated diagnostic thresholds.
OBJECTIVE
OBJECTIVE
The aim of this study was to define the best cut-off scores of the AdAS Spectrum for determining the presence of subthreshold autistic traits as well as a clinically significant autism spectrum disorder (ASD).
METHODS
METHODS
Our sample was composed of 39 patients with full-blown ASD, 73 subjects with autistic traits, and 150 healthy controls. Subjects were evaluated by trained psychiatrists, who performed a clinical diagnosis according to DSM-5 and then assessed with the AdAS Spectrum and the Autism Spectrum Quotient.
RESULTS
RESULTS
Our results showed that the most discriminant cut-off scores were 70 for identifying subjects with full-blown ASD, and 43 for determining the presence of significant autistic traits.
CONCLUSION
CONCLUSIONS
The threshold values proposed here showed satisfying levels of specificity and sensibility, as well as a good agreement with the diagnosis according to DSM-5 criteria, confirming the validity of the AdAS Spectrum as a psychometric tool for measuring ASD-related conditions in the clinical and general population.
Identifiants
pubmed: 33719360
doi: 10.2174/1745017902016010204
pii: CPEMH-16-204
pmc: PMC7931149
doi:
Types de publication
Journal Article
Langues
eng
Pagination
204-211Informations de copyright
© 2020 Dell'Osso et al.
Références
J Child Psychol Psychiatry. 2004 Mar;45(3):421-34
pubmed: 15055363
Neuropsychologia. 2013 Jan;51(1):98-105
pubmed: 23174401
Autism. 2018 Nov;22(8):907-914
pubmed: 28901163
Mol Autism. 2017 Nov 13;8:61
pubmed: 29158888
Case Rep Psychiatry. 2018 Feb 22;2018:1547975
pubmed: 29682383
Arch Gen Psychiatry. 2009 May;66(5):518-26
pubmed: 19414711
Curr Med Chem. 2020;27(31):5119-5136
pubmed: 31448708
Ann Gen Psychiatry. 2014 Oct 16;13(1):33
pubmed: 25328535
Oxid Med Cell Longev. 2018 Nov 5;2018:3717215
pubmed: 30524654
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Autism. 2012 May;16(3):247-60
pubmed: 21949002
Psychiatry Res. 2019 Nov;281:112605
pubmed: 31629303
Iran J Psychiatry. 2018 Apr;13(2):148-153
pubmed: 29997661
Psychiatry Res. 2013 Aug 15;208(3):257-64
pubmed: 23747233
CNS Spectr. 2020 May 26;:1-3
pubmed: 32450944
Psychiatry Res. 2019 Nov;281:112576
pubmed: 31586834
Int J Environ Res Public Health. 2019 Mar 27;16(7):
pubmed: 30934756
Compr Psychiatry. 2017 Feb;73:61-83
pubmed: 27918948
Compr Psychiatry. 2019 May;91:34-38
pubmed: 31003723
J Autism Dev Disord. 2011 Aug;41(8):1076-89
pubmed: 21086033
J Autism Dev Disord. 2009 Nov;39(11):1560-7
pubmed: 19548078
J Am Acad Child Adolesc Psychiatry. 2014 Apr;53(4):398-407.e2
pubmed: 24655649
Gen Hosp Psychiatry. 2013 Jan-Feb;35(1):50-3
pubmed: 23141028
CNS Spectr. 2015 Apr;20(2):100-11
pubmed: 24571962
Brain Res. 2006 Mar 24;1079(1):47-56
pubmed: 16473340
Neuropsychol Rev. 2011 Dec;21(4):360-89
pubmed: 21989834
Neuropsychiatr Dis Treat. 2014 Jul 16;10:1325-32
pubmed: 25075191
J Child Psychol Psychiatry. 2004 Nov;45(8):1431-6
pubmed: 15482503
Clin Pract Epidemiol Ment Health. 2019 Aug 30;15:94-98
pubmed: 31819756
J Autism Dev Disord. 2008 Oct;38(9):1697-709
pubmed: 18324461
PLoS One. 2013 Sep 23;8(9):e75236
pubmed: 24086474
Mol Autism. 2015 May 13;6:24
pubmed: 25973161
Compr Psychiatry. 2018 Feb;81:66-72
pubmed: 29268154
Neuropsychiatr Dis Treat. 2016 Jul 07;12:1651-60
pubmed: 27462158
CNS Spectr. 2020 Dec;25(6):765-773
pubmed: 31747980
Clin Pract Epidemiol Ment Health. 2016 Nov 03;12:120-131
pubmed: 27867417
J Autism Dev Disord. 2001 Feb;31(1):5-17
pubmed: 11439754
Psychiatry Res. 2019 Sep;279:123-129
pubmed: 30366638
Compr Psychiatry. 2018 May;83:7-11
pubmed: 29500962
J Autism Dev Disord. 2019 Mar;49(3):819-833
pubmed: 30361940